Transitional cell carcinoma of the native urinary tract after kidney transplantation: Recommendations following a long-term retrospective analysis

American Journal of the Medical Sciences

Volumn 341, Issue 6, 2011, Pages 478-483

  Tsaur, Igor ^a   Karalis, Athanasios ^a   Blaheta, Roman ^a   Juengel, Eva ^a   Vallo, Stefan ^a   Scheuermann, Ernst Heinrich ^a   Kachel, Heinz Georg ^b   Waaga Gasser, Ana Maria ^c   Chandraker, Anil ^b,d   Obermüller, Nicholas ^a   Probst, Michael ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b KFH Kidney Center   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Dialysis; Immunosuppression; Kidney transplantation; Survival; Transitional cell carcinoma

Indexed keywords

EPIRUBICIN; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; DETRUSOR MUSCLE; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY PELVIS CARCINOMA; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URETER CARCINOMA; URINARY TRACT CARCINOMA;

EID: 79958077773     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31820a87f7     Document Type: Article

References (31)

1. Catena F, Nardo B, Liviano D'Arcangelo G, et al. De novo malig-nancies after organ transplantation. Transplant Proc 2001;33:1858-9.
2. Birkeland SA, Storm JJ, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries. Int J Cancer 1995;60:183-9.
3. Sheil A, Flavel S, Disney A. Cancer development in patients progress-ing to dialysis and renal transplant. Transplant Proc 1985;17:1685-8. (Pubitemid 15108276)
4. Penn I. Malignancy in renal transplant recipients. Saudi J Kidney Dis Transpl 1996;7:1-5.
5. Elkentaoui H, Robert G, Pasticier G, et al. Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French department ofurology and kidney transplan-tation from Bordeaux. Urology 2010;75:126-32.
6. Ochiai T, Asano T, Isono K. Development of malignancies in Japa-nese renal transplant recipients. Transplant Proc 1987;19:2967-70. (Pubitemid 17069558)
7. Li XB, Xing NZ, Wang Y, et al. Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol 2007;15: 53-7.
8. Wu MJ, Lian JD, Yang CR, et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 2004;43:1091-7.
9. Besarani D, Cranston D. Urological malignancy after renal transplan-tation. BJU Int 2007;100:502-5.
10. Neuzillet Y, Cabaniols L, Karam G, et al. Study ofurothelial bladder tumors in renal transplant recipients. Prog Urol 2006;16:343-6. (Pubitemid 44911977)
11. Yuan M, Shi YB, Li ZH, et al. De novo urothelial carcinoma in kidney transplant patients with end-stage aristolochic acid nephropathy in China. Transplant Proc 2009;41:1619-23.
12. Buzzeo BD, Heisey DM, Messing EM. Bladder cancer in renal transplantrecipients. Urology 1997;50:525-8.
13. Stenzl A, Cowan NC, De Santis M, et al. Guidelines on bladder cancer. Muscle-invasive and metastatic. European Association of Urology 2009. Available at: http://www.uroweb.org/fileadmin/tx- eauguidelines/2008/Full/Muscle-Invasive- BC.pdf. Accessed July 23, 2010.
14. Matas AJ, Simmons RL, Kjellstrand CM, et al. Increased incidence ofmalignancy during chronic renal failure. Lancet 1975;1:883-6.
15. Ou JH, Pan CC, Lin J, et al. Transitional cell carcinoma in dialysis patients. Eur Urol 2000;37:90-4. (Pubitemid 30072381)
16. Satoh S, Tsuchiya N, Habuchi T, et al. Renal cell and transitional cell carcinoma in a Japanese population undergoing maintenance dialysis. J Urol 2005;174:1749-53. (Pubitemid 41546926)
17. Palvio DH, Andersen JC, Falk E. Transitional cell tumors of the renal pelvis and ureter associated with capillarosclerosis indicating analgesic abuse. Cancer 1987;59:972-6. (Pubitemid 17024654)
18. Stefanovic V, Radovanovic Z. Balkan. Endemic nephropathy and associated urothelial cancer. Nat Clin Pract Urol 2008;5:105-12. (Pubitemid 351248099)
19. Previte SR, Murata GT, Olsson CA. Hematuria in renal transplant recipients. Ann Surg 1978;187:219-22. (Pubitemid 8283536)
20. Ehdaie B, Stukenborg GJ, Theodorescu D. Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer. J Urol 2009;182:1482-7.
21. Raitanen MP, Aine R, Rintala E, et al. Differences between local and review urinary cytology and diagnosis ofbladder cancer: an interob-server multicenter analysis. Eur Urol 2002;41:284-9. (Pubitemid 35303426)
22. Zein TA, Milad MF. Urine cytology in bladder tumors. Int Surg 1991;76:52-4.
23. Vaidya A, Soloway MS, Hawke C, et al. De novo muscle invasive bladder cancer: is there a change in trend? J Urol 2001;165:47-50.
24. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
25. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5. (Pubitemid 35461559)
26. Böhle A, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis ofcom-parative studies on tumor progression. Urology 2004;63:682-7.
27. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. Mainte-nance bacillus Calmette-Guerin for Ta, T1 bladder tumors is not associated with increased toxicity: results from a European Organisa-tion for Research and Treatment ofCancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429-34. (Pubitemid 37185667)
28. Palou J, Angerri O, Segarra J, et al. Intravesical bacillus Calmette-Guerin for the treatment ofsuperficial bladder cancer in renal transplant recipients. Transplantation 2003;76:1514-6. (Pubitemid 37467704)
29. Rischmann P, Desgrandchamps F, Malavaud B, et al. BCG intra-vesical instillations: recommendations for side-effects management. Eur Urol 2000;37(suppl 1):33-6. (Pubitemid 30076963)
30. Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 2003;46(suppl):105-15.
31. Gifford RR, Wofford JE, Edwards WG Jr. Carcinoma of the bladder in renal transplant patients. A case report and collective review ofcases. Clin Transpl 1998;12:65-9. (Pubitemid 28112328)